Aspergillosis Clinical Trial
Official title:
Diagnostic Study on the Performance of an Aspergillus-specific Nested PCR Assay in Cerebrospinal Fluid Samples of Immunocompromised Patients for Detection of Central Nervous System Aspergillosis
Central nervous system (CNS) invasive aspergillosis (IA) is a fatal complication in immunocompromised patients. Confirming the diagnosis is rarely accomplished as invasive procedures are hampered by neutropenia and low platelet count. Cerebrospinal fluid (CSF) cultures or galactomannan (GM) regularly yield negative results thus suggesting the need for improving diagnostics. Therefore the performance of an established Aspergillus-specific nested PCR in CSF samples of immunocompromised patients with suspicion of CNS IA will be evaluated.
Central nervous system (CNS) invasive aspergillosis (IA) is a fatal complication in immunocompromised patients with hematological malignancies. Confirming the diagnosis is rarely accomplished as invasive procedures are impaired by neutropenia and low platelet count. Cerebrospinal fluid (CSF) cultures or galactomannan (GM) regularly yield negative results thus suggesting the need for improving diagnostic tools. Therefore the performance of an established Aspergillus-specific nested PCR assay in CSF samples of immunocompromised patients with suspicion of CNS IA will be evaluated. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Suspended |
NCT01887457 -
Individualisation of Voriconazole Antifungal Therapy Antifungal Therapy
|
Phase 2 | |
Completed |
NCT00940017 -
A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects
|
Phase 4 | |
Terminated |
NCT03905447 -
The Effect of Early Treatment of PC945 on Aspergillus Fumigatus Lung Infection in Lung Transplant Patients.
|
Phase 2 | |
Recruiting |
NCT04744454 -
Post Marketing Surveillance (PMS) Study of Cresemba in Korea.
|
||
Completed |
NCT02715570 -
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of PC945
|
Phase 1 | |
Withdrawn |
NCT01622595 -
UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients
|
N/A | |
Completed |
NCT00001937 -
Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant Patients
|
Phase 3 | |
Completed |
NCT04935463 -
Mucormycosis in COVID-19
|
||
Withdrawn |
NCT01188759 -
Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects
|
Phase 3 | |
Completed |
NCT00473252 -
Surveillance of Fungal Infections During Construction Activity
|
N/A | |
Completed |
NCT00037206 -
A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).
|
Phase 2/Phase 3 | |
Completed |
NCT04818853 -
COVID-19 Associated Pulmonary Aspergillosis (CAPA) and Other Invasive Fungal Infections (IFI)
|
||
Completed |
NCT00412893 -
Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis
|
Phase 3 | |
Recruiting |
NCT06135597 -
Immune Regulation in Chronic Aspergillus Infection After COVID-19 Infection
|
||
Terminated |
NCT02646800 -
Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp
|
Phase 4 | |
Completed |
NCT00854607 -
An Observational Study of Fungal Biomarkers (MK-0000-089)
|
N/A | |
Completed |
NCT00388167 -
Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection
|
Phase 4 | |
Completed |
NCT05065658 -
Posaconazole Prophylaxis for CAPA Prevention in Critically-Ill Patients
|
||
Completed |
NCT00005912 -
Voriconazole to Prevent Systemic Fungal Infections in Children
|
Phase 1 | |
Completed |
NCT04431804 -
THYME AND CARVACROLL Nanoparticle Effect on Fungi
|